Only 1 study to date, using genome-wide association studies of cerebrospinal fluid tau levels to identify risk variants for Alzheimer disease, has identified GLIS3 as a significant locus for the development of Alzheimer disease (25). Here, MAPT is linked to Alzheimer disease.